WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 44'6601 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 47'8041 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 4'688  4'675  4'671  4'668  4'653  3'842  3'563  3'431 
Births 68  70  71  72  73  58  51  72 
Surviving infants 68  70  71  72  72  57  51  71 
Pop. less than 5 years 353  359  365  369  368  269  279  361 
Pop. less than 15 years 1'021  1'012  1'004  993  978  821  980  1'043 
Female 15-49 years 1'117  1'132  1'150  1'170  1'186  1'021  882  785 

Number of reported cases

(Click for retrospective incidence data for Ireland)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  33  51  107  285  556  1'106 
Mumps
ChartChart
  2'016  762  228  170  177 
Pertussis
ChartChart
  118  73  175  458  229  803  547 
Polio*
ChartChart
 
Rubella
ChartChart
  10 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Ireland)
Vaccine year result method % card seen                                                
BCG          87  86  86  80  85 
DTP1         
DTP3          95  96  96  95  95  86  65  34 
DTP4         
IPV1         
HepB_BD         
HepB3          95  95  95  95  95 
Hib3          95  96  95  95  95  85 
JapEnc         
MCV1          93  93  92  92  92  79 
MCV2         
PCV1         
PCV3          92  92  91  91  90 
Pol3          95  96  96  95  95  86  81  72 
Rota1         
RotaC         
Rubella1          93  93  92  92  92 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Ireland)
BCG
ChartChart
  77  74  76  42  41  89  84 
DTP1
ChartChart
  98  98  98  98  98  95  85  59 
DTP3
ChartChart
  95  96  96  95  95  86  65  34 
HepB3
ChartChart
  95  95  95  95  95 
HepB_BD
ChartChart
 
Hib3
ChartChart
  95  96  95  95  95  85 
MCV1
ChartChart
  93  93  92  92  92  79  78 
MCV2
ChartChart
 
PCV3
ChartChart
  92  92  91  91  90 
Pol3
ChartChart
  95  96  96  95  95  86  81  72 
RCV1
ChartChart
  93  93  92  92  92  79  78 
RotaC
ChartChart
 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; No defined risk groups
DTaPHibHepIPV 2, 4, 6 months; Yes
DTaPIPV 4-5 years; Yes
HIB 13 months; Yes and defined risk groups
HPV 12-13 years; +5 months; Yes
HepB_Adult 1st contact; +1, +5 months; Yes defined risk groups
Influenza_Adult Yes elderly, pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12 months; 4-5 years; Yes Also given to HCW and during outbreaks and other risk groups
MenC_conj 4, 13 months; 12-13 years; Yes until 30/06/2015 schedule was 4, 6, 13 months
Pneumo_conj 2, 6, 12 months; Yes
Pneumo_ps >=65 years; Yes And children >=2 years at risk;
Tdap 12-13 years; Yes every 10 years and defined risk groups

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   No  Yes    Yes  Yes  NA 
What years does the MYP cover? number     2013-2014    2011 -2012  2010 -2011   
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 25  25  38  25  13 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND     Yes    Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR     Yes    Yes  Yes   

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%     90    90  90   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.